tetano
Editor, Senior Moderator
Ear Nose Throat J
. 2020 Dec 1;145561320977464.
doi: 10.1177/0145561320977464. Online ahead of print.
Taste and Smell Impairment in Critically Ill Patients With COVID-19: An Intensive Care Unit Study
Pınar Sayın[SUP] 1 [/SUP], Mustafa Altınay[SUP] 1 [/SUP], Ayse Surhan Cınar[SUP] 1 [/SUP], Hacı Mustafa Ozdemir[SUP] 2 [/SUP]
Affiliations
Abstract
Objective: To determine taste and smell impairment rates in patients with coronavirus disease 2019 (COVID-19) who were hospitalized in the intensive care unit (ICU).
Methods: Between March 2020 and May 2020, patients with COVID-19 hospitalized in the ICU were enrolled in this study. Upon discharge, patients were telephoned and asked to complete a survey related to taste and smell impairment. Characteristics were compared between patients with and without taste and/or smell impairment.
Results: Fifty-two patients were enrolled (mean age, 61.32 ? 12.53 years; mean ICU stay, 10.19 ? 10.24 days). Age, sex, type/number of comorbid diseases, most ICU support modalities, and ICU stay duration did not significantly differ between groups. Patients in group B required more high-flow nasal oxygen therapy than patients in group A (P = .010). In total, 22 (42.3%) of 52 patients experienced taste and/or smell impairment. Three patients experienced isolated smell impairment and one patient experienced isolated taste impairment. Among the 21 patients who experienced smell impairment, 18 (85.78%) experienced hyposmia (mean visual analog scale [VAS] score: 6.33 ? 0.97), while 3 (14.28%) experienced anosmia. Among the 19 patients who experienced taste impairment, 16 (84.22%) experienced hypogeusia (mean VAS score: 6.43 ? 1.03) and 3 (15.78%) experienced ageuisa. Among 22 patients who experienced taste and/or smell impairment, 15 (68.18%) patients (n = 15/22) experienced smell and/or taste impairment before the ICU stay, while 7 (31.82%) patients (n = 7/22) experienced impairment during the ICU stay. Overall, 28.84% (n = 15/52) of the patients experienced taste and/or smell impairment before the ICU stay.
Conclusions: Patients who were hospitalized in the ICU experienced lower rates of taste and/or smell impairment. Some patients experienced taste and/or smell impairment during the ICU stay.
Keywords: COVID-19; anosmia; chemosensory; hyposmia; intensive care.
. 2020 Dec 1;145561320977464.
doi: 10.1177/0145561320977464. Online ahead of print.
Taste and Smell Impairment in Critically Ill Patients With COVID-19: An Intensive Care Unit Study
Pınar Sayın[SUP] 1 [/SUP], Mustafa Altınay[SUP] 1 [/SUP], Ayse Surhan Cınar[SUP] 1 [/SUP], Hacı Mustafa Ozdemir[SUP] 2 [/SUP]
Affiliations
- PMID: 33258690
- DOI: 10.1177/0145561320977464
Abstract
Objective: To determine taste and smell impairment rates in patients with coronavirus disease 2019 (COVID-19) who were hospitalized in the intensive care unit (ICU).
Methods: Between March 2020 and May 2020, patients with COVID-19 hospitalized in the ICU were enrolled in this study. Upon discharge, patients were telephoned and asked to complete a survey related to taste and smell impairment. Characteristics were compared between patients with and without taste and/or smell impairment.
Results: Fifty-two patients were enrolled (mean age, 61.32 ? 12.53 years; mean ICU stay, 10.19 ? 10.24 days). Age, sex, type/number of comorbid diseases, most ICU support modalities, and ICU stay duration did not significantly differ between groups. Patients in group B required more high-flow nasal oxygen therapy than patients in group A (P = .010). In total, 22 (42.3%) of 52 patients experienced taste and/or smell impairment. Three patients experienced isolated smell impairment and one patient experienced isolated taste impairment. Among the 21 patients who experienced smell impairment, 18 (85.78%) experienced hyposmia (mean visual analog scale [VAS] score: 6.33 ? 0.97), while 3 (14.28%) experienced anosmia. Among the 19 patients who experienced taste impairment, 16 (84.22%) experienced hypogeusia (mean VAS score: 6.43 ? 1.03) and 3 (15.78%) experienced ageuisa. Among 22 patients who experienced taste and/or smell impairment, 15 (68.18%) patients (n = 15/22) experienced smell and/or taste impairment before the ICU stay, while 7 (31.82%) patients (n = 7/22) experienced impairment during the ICU stay. Overall, 28.84% (n = 15/52) of the patients experienced taste and/or smell impairment before the ICU stay.
Conclusions: Patients who were hospitalized in the ICU experienced lower rates of taste and/or smell impairment. Some patients experienced taste and/or smell impairment during the ICU stay.
Keywords: COVID-19; anosmia; chemosensory; hyposmia; intensive care.